|
Re: Exempt Distribution - 2022-04-14
|
8
|
Resverlogix Corp.
|
Apr 19, 2022 11:23AM
|
|
Re: Exempt Distribution - 2022-04-14
|
6
|
Resverlogix Corp.
|
Apr 18, 2022 11:21AM
|
|
Re: Exempt Distribution - 2022-04-14
|
6
|
Resverlogix Corp.
|
Apr 18, 2022 01:28PM
|
|
Re: Exempt Distribution
|
2
|
Resverlogix Corp.
|
Feb 17, 2021 03:30PM
|
|
Re: everything r v x is down 4% to around 24%
|
6
|
Resverlogix Corp.
|
Jan 27, 2021 01:17PM
|
|
Re: Eversana??
|
1
|
Resverlogix Corp.
|
Jan 08, 2024 10:01AM
|
|
Re: Eversana
|
3
|
Resverlogix Corp.
|
Jul 08, 2021 10:48AM
|
|
Re: Ethics Approval?
|
2
|
Resverlogix Corp.
|
Oct 12, 2021 05:35PM
|
|
Re: Ethics Approval?
|
|
Resverlogix Corp.
|
Oct 12, 2021 07:39PM
|
|
Re: Ethics Approval?
|
2
|
Resverlogix Corp.
|
Oct 13, 2021 04:28PM
|
|
Re: ESC Poster on Vascular Inflammation, Calcification and Plaque Vulnerability
|
2
|
Resverlogix Corp.
|
Sep 03, 2019 07:45PM
|
|
Re: Epigenetics market size
|
1
|
Zenith Epigenetics
|
Jan 16, 2024 07:41PM
|
|
Re: Epigenetics market size
|
6
|
Zenith Epigenetics
|
Jan 16, 2024 02:18PM
|
|
Re: Epigenetics and Coronavirus
|
4
|
Resverlogix Corp.
|
Mar 23, 2020 11:22AM
|
|
Re: Enthusiasm? NOT!
|
3
|
Zenith Epigenetics
|
Oct 28, 2021 03:55PM
|
|
Re: early report imo
|
3
|
Resverlogix Corp.
|
Jul 04, 2022 03:49PM
|
|
Re: early report imo
|
2
|
Resverlogix Corp.
|
Jul 04, 2022 04:05PM
|
|
Re: early report imo
|
1
|
Resverlogix Corp.
|
Jul 04, 2022 04:45PM
|
|
Re: Earliest minute/hour
|
2
|
Resverlogix Corp.
|
Sep 29, 2019 12:13PM
|
|
Re: Drugmakers, scientists begin the hunt for long COVID treatments
|
4
|
Resverlogix Corp.
|
Mar 28, 2022 10:01AM
|
